Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.850
-0.010 (-0.54%)
At close: Apr 28, 2026, 4:00 PM EDT
1.880
+0.030 (1.62%)
After-hours: Apr 28, 2026, 7:36 PM EDT
Milestone Pharmaceuticals Employees
Milestone Pharmaceuticals had 38 employees as of December 31, 2025. The number of employees increased by 5 or 15.15% compared to the previous year.
Employees
38
Change (1Y)
5
Growth (1Y)
15.15%
Revenue / Employee
$40,684
Profits / Employee
-$1,659,421
Market Cap
226.90M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 146 |
| Voyager Therapeutics | 141 |
| Heron Therapeutics | 128 |
| Adagene | 128 |
| Orchestra BioMed Holdings | 86 |
| Keros Therapeutics | 78 |
| Camp4 Therapeutics | 48 |
| ALX Oncology Holdings | 43 |
MIST News
- 15 days ago - Milestone Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 18 days ago - Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT - GlobeNewsWire
- 21 days ago - Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 26 days ago - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - GlobeNewsWire
- 5 weeks ago - Why Milestone Pharma Stock Is Taking A Dive Today - Benzinga
- 5 weeks ago - Milestone Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT - GlobeNewsWire